Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?

Toward the end of last year, Kodiak Sciences decided to reboot the development program of its lead candidate, tarcocimab (a novel anti-VEGF ABC), after witnessing positive top-line results from its phase III GLOW study evaluating the same in moderately severe to severe non-proliferative diabetic retinopathy (NPDR). Building on the success of the GLOW1 study, KOD initiated the pivotal phase III GLOW2 study evaluating tarcocimab in diabetic retinopathy, which is actively enrolling patients, during the fourth ...